Teva, Pfizer settle on Viagra generic date

Share this article:

Teva announced yesterday afternoon that it had settled patent litigation with Pfizer and that the generics firm will be allowed to sell a copycat version of the blockbuster ED drug Viagra (sildenafil citrate) prior to the pill's official LOE date. Viagra's patent lapses in 2020, but this new settlement deal, terms of which the companies are keeping close to the vest, will allow the Israeli drug firm to roll out its copy by December 2017, Teva said, adding that it will pay a royalty to Pfizer for licensing. Its sildenafil ANDA has received tentative approval from the FDA. As of September 2013, Viagra had annual US sales of about $1.2 billion, according to IMS data cited by Teva.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.